



---

## Correction

---

# Correction to: Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies

Megan E. McMahon<sup>1,17</sup> · Alexander Abbott<sup>2</sup> · Yelizaveta Babayan<sup>3</sup> · Jenny Carhart<sup>4</sup> · Chi-wan Chen<sup>5</sup> · Elke Debie<sup>6</sup> · Mingkun Fu<sup>7</sup> · Cherokee Hoaglund-Hyzer<sup>3</sup> · Andrew Lennard<sup>8</sup> · Hanlin Li<sup>9</sup> · Tony Mazzeo<sup>10</sup> · Lori McCaig<sup>11</sup> · Sylvine Pischel<sup>12</sup> · Fenghe Qiu<sup>13</sup> · Dennis Stephens<sup>14</sup> · Robert Timpano<sup>1</sup> · Debra Webb<sup>14</sup> · Chad Wolfe<sup>3</sup> · Kayla Woodlief<sup>15</sup> · Yan Wu<sup>16</sup>

Published online 15 November 2021

Correction to: The AAPS Journal volume 23, Article number: 107 (2021)

<https://doi.org/10.1208/s12248-021-00641-6>

The original online version of this article was revised to add the graphical abstract.

The original article has been corrected.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1208/s12248-021-00641-6>.

<sup>1</sup> Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, USA

<sup>2</sup> Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, UK

<sup>3</sup> Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA

<sup>4</sup> Takeda Pharmaceuticals Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, USA

<sup>5</sup> Pfizer Inc., 8455 Colesville Rd, Silver Spring, Maryland 20910, USA

<sup>6</sup> Janssen R&D A Division of Janssen Pharmaceutica NV, Turnhoutseweg 302340, Beerse, Belgium

<sup>7</sup> Sunovion Pharmaceutical Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752, USA

<sup>8</sup> Amgen Ltd., 1 Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, UK

<sup>9</sup> Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, USA

<sup>10</sup> Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, USA

<sup>11</sup> Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021, USA

<sup>12</sup> GlaxoSmithKline, Great West Road, Brentford TW8 9GS, Middlesex, UK

<sup>13</sup> Boehringer Ingelheim, 900 Ridgebury Road, Ridgefield, Connecticut 06877, USA

<sup>14</sup> AbbVie, 1 N Waukegan Road, North Chicago, Illinois 60064, USA

<sup>15</sup> 225 Binney Street, Cambridge, Massachusetts, USA

<sup>16</sup> Merck & Co., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, USA

<sup>17</sup> To whom correspondence should be addressed. (e-mail: [megan.mcmahon@pfizer.com](mailto:megan.mcmahon@pfizer.com))